High angiogenic potential in an in vivo rat corneal model is associated with shorter disease-free survival in low-grade oligodendrogliomas.

Autor: Ozkan A; Institute of Neurological Sciences, Neurosurgical Research Center, Marmara University, PK 53 Maltepe, Istanbul 34853, Turkey., Guduk M, Atabay KD, Uyar SB, Seker A, Konya D, Pamir MN, Kilic T
Jazyk: angličtina
Zdroj: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia [J Clin Neurosci] 2011 Jan; Vol. 18 (1), pp. 109-13. Date of Electronic Publication: 2010 Oct 12.
DOI: 10.1016/j.jocn.2010.05.034
Abstrakt: This study aimed to examine the association between time to tumor recurrence, angiogenic potential and tumor contrast-enhancement. Tumor samples were taken from 20 patients with low-grade oligodendroglioma and examined for their angiogenic potential using an in vivo rat corneal model of angiogenesis. Patients were evaluated for tumor contrast enhancement prior to surgical excision using MRI and they were followed for tumor recurrence. Patients who had tumors without contrast enhancement had longer disease-free survival (median time to tumor recurrence, 72 months) compared to those who had tumors with contrast enhancement (median, 42 months; p=0.0068). Based on corneal angiogenesis assay results, a high angiogenic potential was associated with a significantly shorter disease-free survival. Our findings suggest that radiological contrast enhancement and a high angiogenic potential based on an in vivo corneal angiogenesis assay were related to a shorter disease-free survival. This might have important prognostic implications in patients with low-grade oligodendrogliomas.
(Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: